Accueil   Diary - News   All news Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao

Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao

 

 

• In this study, the BioChaperone Lispro formulation containing insulin lispro from Tonghua Dongbao demonstrated similar ultra-rapid pharmacokinetic, pharmacodynamic, and safety profiles when compared to a BioChaperone Lispro formulation containing insulin lispro Humalog®


• In nine previous studies, a BC Lispro formulation using insulin lispro (Humalog®) demonstrated an Ultra-Rapid profile which significantly improved glycemic control compared to Humalog®, Novolog® and Fiasp®


• Results from this study complete the dossier for BioChaperone Lispro, employing insulin lispro from Tonghua Dongbao, required for initiation of Phase 3 studies in China, Europe, and the US


• This study confirms the performance of the insulin lispro drug substance supplied by our strategic partner, Tonghua Dongbao

 


Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today positive results from a clinical pharmacology study comparing BioChaperone (BC) Lispro formulations employing insulin lispro from two different sources, a biosimilar from Tonghua Dongbao (THDB) and the brand, Humalog®, from Eli Lilly.

 

 

Read the presse release